Abstract: SA-PO454
Clinician and Patient Support Through Supply Chain Innovation During the COVID-19 Pandemic
Session Information
- Hemodialysis and Frequent Dialysis: Clearance, Technology, Infection
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Khangura, Ramnik S., Outset Medical, San Jose, California, United States
- Sandhu, Kulwant, Outset Medical, San Jose, California, United States
- D'Alessandri-Silva, Cynthia J., Outset Medical, San Jose, California, United States
- Aragon, Michael A., Outset Medical, San Jose, California, United States
Background
Since March 2020, the COVID-19 Pandemic has critically impacted the global supply chain from raw materials to devices and supplies. As a result, many hospitals’ and dialysis providers’ capacity to provide care for patients in ICUs and dialysis units was materially impacted. To ensure patients received the necessary life-saving dialysis treatments from the ICU to Home with Tablo, it was critical to implement a new, long term global supply chain strategy. Here we report the impact of an innovative supply chain initiative to meet these challenges.
Methods
Retrospective analysis of supply chain performance metrics from Dec 2020-Dec 2021 assessed monthly for on-time delivery, inventory, allocation events and overall parts shipped. During March and April of 2020, Outset’s supply chain team implemented 3 strategic initiatives aimed at improving risk analysis, upstream sourcing and logistics management. Risk analysis improvements included investment in software analytics and application of AI to improve transparency for rapid decisions. Upstream sourcing developed expertise in the full life cycle of every component and category of the device to secure supplies with methods including dual source or near source. Logistics focused on long term stability and localization of goods by partnering with third party distribution and logistics providers to utilize a wider range of supply transport options.
Results
Over the 13 months period, total treatments delivered increased by 125%. The mean On Time Delivery performance over the same period was 96% (min 92%, max 98%), better than the internal target of 95%. (Fig 1) There were no occurrences of delivery interruption or implementation of supply allocation to any hospitals, clinics or home dialysis patients.
Conclusion
Sustainable innovation in Tablo’s console and cartridge supply chain successfully supported the increased demand for dialysis equipment and supplies and ensured reliable delivery of critically needed treatment related supplies for clinicians and patients using Tablo throughout the peak of the pandemic.